Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice.
Hematocrit
Myeloproliferative disorders
Polycythemia vera
Retrospective studies
Ruxolitinib
Thrombosis
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
25 Apr 2024
25 Apr 2024
Historique:
received:
15
01
2024
accepted:
29
03
2024
medline:
25
4
2024
pubmed:
25
4
2024
entrez:
25
4
2024
Statut:
aheadofprint
Résumé
Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by unregulated red blood cell production resulting in elevated hemoglobin and/or hematocrit levels. Patients often have symptoms such as fatigue, pruritus, and painful splenomegaly, but are also at risk of thrombosis, both venous and arterial. Ruxolitinib, a selective Janus kinase inhibitor, is approved by the US Food and Drug Administration as second-line cytoreductive treatment after intolerance or inadequate response to hydroxyurea. Although ruxolitinib has been widely used in this setting, limited data exist in the literature on ruxolitinib treatment patterns and outcomes among patients with PV in routine clinical practice. We report a retrospective, observational, cohort study of patients treated for PV with ruxolitinib across three US centers (academic and regional practice) from December 2014-December 2019. The study included 69 patients, with a median follow-up duration of 3.7 years (95% CI, 2.9-4.4). Our data demonstrate very high rates of hematocrit control (88% of patients by three months and 89% by six months); few patients required dose adjustments or suspension. No arterial thromboses were observed; however, the follow-up duration does not allow for the generation of meaningful conclusions from this. Three patients had thrombotic events; one was in the setting of a second malignancy, one post-operative, and a third related to prolonged immobility. We also found that 28% of patients initiated ruxolitinib as a result of poorly controlled platelet counts, second only to hydroxyurea intolerance (46%) as a reason to start therapy. In clinical practice, ruxolitinib continues to be effective in controlling hematocrit levels after three and six months of treatment in patients and is associated with low thrombotic risk.
Identifiants
pubmed: 38662203
doi: 10.1007/s00277-024-05735-7
pii: 10.1007/s00277-024-05735-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Gianelli U, Thiele J, Orazi A, Gangat N, Vannucchi AM, Tefferi A, Kvasnicka HM (2023) International Consensus classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms. Virchows Arch 482(1):53–68. https://doi.org/10.1007/s00428-022-03480-8
doi: 10.1007/s00428-022-03480-8
pubmed: 36580136
Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F et al (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 30(33):4098–4103. https://doi.org/10.1200/jco.2012.42.3863
doi: 10.1200/jco.2012.42.3863
pubmed: 23071245
pmcid: 4872304
Gruppo Italiano Studio Policitemia (1995) Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 123(9):656–664. https://doi.org/10.7326/0003-4819-123-9-199511010-00003
doi: 10.7326/0003-4819-123-9-199511010-00003
Griesshammer M, Kiladjian J-J, Besses C (2019) Thromboembolic events in polycythemia vera. Ann Hematol 98(5):1071–1082. https://doi.org/10.1007/s00277-019-03625-x
doi: 10.1007/s00277-019-03625-x
pubmed: 30848334
pmcid: 6469649
Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874–1881. https://doi.org/10.1038/leu.2013.163
doi: 10.1038/leu.2013.163
pubmed: 23739289
pmcid: 3768558
Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R et al (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32(5):1057–1069. https://doi.org/10.1038/s41375-018-0077-1
doi: 10.1038/s41375-018-0077-1
pubmed: 29515238
pmcid: 5986069
Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R et al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426–435. https://doi.org/10.1056/NEJMoa1409002
doi: 10.1056/NEJMoa1409002
pubmed: 25629741
pmcid: 4358820
Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S et al (2020) Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol 7(3):e226–e237. https://doi.org/10.1016/s2352-3026(19)30207-8
doi: 10.1016/s2352-3026(19)30207-8
pubmed: 31982039
pmcid: 8938906
Coltoff A, Mesa R, Gotlib J, Shulman J, Rampal RK, Siwoski O, Yacoub A, Moliterno A, Yang A, Braunstein E et al (2020) Real-world outcomes of ruxolitinib treatment for polycythemia vera. Clin Lymphoma Myeloma Leuk 20(10):697–703e691. https://doi.org/10.1016/j.clml.2020.05.019
doi: 10.1016/j.clml.2020.05.019
pubmed: 32624445
pmcid: 8900057
Alvarez-Larrán A, Garrote M, Ferrer-Marín F, Pérez-Encinas M, Mata-Vazquez MI, Bellosillo B, Arellano-Rodrigo E, Gómez M, García R, García-Gutiérrez V et al (2022) Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. Cancer 128(13):2441–2448. https://doi.org/10.1002/cncr.34195
doi: 10.1002/cncr.34195
pubmed: 35417564
Altomare I, Parasuraman S, Paranagama D, Kish J, Lord K, Yu J, Colucci P (2021) Real-world dosing patterns of ruxolitinib in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea. Clin Lymphoma Myeloma Leuk 21(11):e915–e921. https://doi.org/10.1016/j.clml.2021.06.023
doi: 10.1016/j.clml.2021.06.023
pubmed: 34353779
Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C et al (2017) Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol 18(1):88–99. https://doi.org/10.1016/s1470-2045(16)30558-7
doi: 10.1016/s1470-2045(16)30558-7
pubmed: 27916398
Pepe S, Rossi E, Trawinska M, Tatarelli C, Di Veroli A, Maurillo L, Romano A, Crescenzi SL, di Toritto TC, Tafuri A et al (2022) Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group. Ann Hematol 101(6):1275–1282. https://doi.org/10.1007/s00277-022-04815-w
doi: 10.1007/s00277-022-04815-w
pubmed: 35318505
Tremblay D, Ronner L, Podoltsev N, Gotlib J, Heaney M, Kuykendall A, O’Connell C, Shammo JM, Fleischman A, Mesa R et al (2021) Ruxolitinib discontinuation in polycythemia vera: patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leuk Res 109:106629. https://doi.org/10.1016/j.leukres.2021.106629
doi: 10.1016/j.leukres.2021.106629
pubmed: 34082375
Kremyanskaya M, Kuykendall AT, Pemmaraju N, Ritchie EK, Gotlib J, Gerds A, Palmer J, Pettit K, Nath UK, Yacoub A et al (2024) Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera. N Engl J Med 390(8):723–735. https://doi.org/10.1056/NEJMoa2308809
doi: 10.1056/NEJMoa2308809
pubmed: 38381675